If you liked this article you might like

Cramer: The Answer to This Market: Part 1
Pharma Has History of Price Gouging, Mylan Should Be No Surprise
Why EpiPen, Why Now? Analysts Explain the Timing of Mylan's Trouble
Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation